Health
Moderna launches COVID-19 vaccine booster study to address new variants – PMLiVE
First participants receive company’s modified vaccine candidates
Moderna has begun giving booster doses of its COVID-19 vaccine to trial participants as part of an amendment to a phase 2 clinical study.
The phase 2 trial amendment has enrolled 60 participants who have already received Moderna’s original mRNA-1273 vaccine. They will receive a single booster dose of a modified candidate addressing the B.1.351 variant or a multivalent booster candidate.
The variant-specific booster candidate – mRNA-1273.351 – encodes for the spike protein of the SARS-CoV-2 variant…
-
General20 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General23 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
Noosa News22 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland
-
General21 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience